Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The new era of AML therapy: current standards and emerging targets.

International journal of clinical oncology - 1 Jul 2026

Hosono Naoko

Abstract excerpt

Over the past decade, AML therapy has evolved from the uniform "7 + 3" regimen toward a personalized approach. This transition integrates molecular genetic profiles with clinical fitness, driven by the genomic elucidation of AML and the development of selective targeted agents. Key advancements include the integration of FLT3 inhibitors into intensive chemotherapy and the emergence of venetoclax. When combined...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Cytarabine
Share to Daunorubicin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Histone-Lysine N-Methyltransferase

Share to Myeloid-Lymphoid Leukemia Protein

Share to Nucleophosmin

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 41995989
DOI: 10.1007/s10147-026-03038-7
PMCID: PMC13303667

Genes

IDH1
FLT3
KMT2A
NPM1
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The new era of AML therapy: current standards and emerging targets.PMID 41995989Read ↗

Advancements and Challenges in the Treatment of AML.Semantic proximity Read ↗

Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid LeukemiaSemantic proximity Read ↗

Recent advances in targeted therapies in acute myeloid leukemia.Semantic proximity Read ↗

Updates on targeted therapies for acute myeloid leukaemia.Semantic proximity Read ↗

An overview of novel therapies in advanced clinical testing for acute myeloid leukemia.Semantic proximity Read ↗

How I treat acute myeloid leukemia in the era of new drugs.Semantic proximity Read ↗

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?Semantic proximity Read ↗

Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting ChallengesSemantic proximity Read ↗

Update on rational targeted therapy in AMLSemantic proximity Read ↗

Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New AgentsSemantic proximity Read ↗

Latest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted TreatmentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.